Open AccessThe Outcome of Single-dose Cefuroxime Treatment in Patients with Pharyngeal Gonorrhea
Author(s) -
C Graudal,
Anne Cathrine Bollerup,
Kamma Lange,
Kirsten Seier,
Inga Lind
Publication year - 1985
Publication title -
sexually transmitted diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.507
H-Index - 105
eISSN - 1537-4521
pISSN - 0148-5717
DOI - 10.1097/00007435-198501000-00010
Subject(s) - gonorrhea , medicine , cefuroxime , neisseria gonorrhoeae , probenecid , regimen , pharynx , antibiotics , gastroenterology , surgery , microbiology and biotechnology , immunology , human immunodeficiency virus (hiv) , biology
This study of single-dose cefuroxime treatment of pharyngeal gonorrhea included 13 patients from whose throat specimens taken on the day of treatment Neisseria gonorrhoeae was isolated and who returned for follow-up examinations one and two weeks later. The regimen used was cefuroxime (1.5 g im) plus probenecid (1 g orally). The treatment failed in six patients (46%). Failure of treatment was not associated with decreased in vitro susceptibility of the infecting strain to cefuroxime. In pharyngeal gonorrhea the diagnosis by culture and effective control of treatment require repeated sampling for bacteriologic examinations.